Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

Rhea-AI Summary

Organon (NYSE: OGN) will release its Q1 2022 financial results on May 5, 2022, before an 8:30 a.m. EDT conference call. The call will be accessible via webcast on the company's website, with a replay available approximately two hours later. Analysts and investors must register in advance using conference ID# 6895016. Formed as a spin-off from Merck (NYSE: MRK), Organon focuses on women's health, boasting a diverse portfolio of over 60 medicines. The company aims to collaborate with biopharmaceutical innovators while maintaining strong cash flows for future growth.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.

Institutional investors and analysts interested in participating in the call must register in advance using conference ID# 6895016 and by clicking on this link: http://www.directeventreg.com/registration/event/6895016. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.

About Organon
Organon is a global healthcare company formed through a spin-off from Merck & Co., Inc., Rahway, NJ, USA, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005089/en/

Media:

Karissa Peer

(614) 314-8094



Kate Vossen

(732) 675-8448



Investor:

Jennifer Halchak

(201) 275-2711



Edward Barger

(267) 614-4669

Source: Organon & Co.

FAQ

When will Organon release its first quarter 2022 financial results?

Organon will release its Q1 2022 financial results on May 5, 2022.

What time is the Organon conference call scheduled for?

The Organon conference call is scheduled for 8:30 a.m. EDT on May 5, 2022.

How can I access the Organon conference call?

The conference call can be accessed via webcast on Organon's website.

Do I need to register to participate in the Organon earnings call?

Yes, participants must register in advance using conference ID# 6895016.

What is Organon's focus as a company?

Organon focuses on improving women's health with a portfolio of over 60 medicines.

Which company spun off Organon?

Organon was formed as a spin-off from Merck & Co. (NYSE: MRK).